Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70°C or less

International Journal of Biological Markers

Volumn 22, Issue 3, 2007, Pages 206-213

  Scaramuzzino, D A ^a   Schulte, K ^b   Mack, B N ^a   Soriano, T F ^a   Fritsche, H A ^c  

^a DOCRO Inc   (United States)

^b Ellis Hospital   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Collection and storage; Prostate cancer; Prostate specific antigen; Serum; Stability

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYZER; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BLOOD STORAGE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FREEZE THAWING; HUMAN; LOW TEMPERATURE; MALE; PROSTATE CANCER; PROTEIN STABILITY; REGRESSION ANALYSIS; STORAGE TEMPERATURE;

EID: 36048955792     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4454     Document Type: Article

References (32)

1. Jemal A, Siegal R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. 1-antichymotrypsin complexed in vitro. Biotechnol Appl Biochem 1998; 27: 249-57.
3. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23.
4. Neuwirth H. Marin Urology. Prostate specific antigen (PSA). http://marinurology.com/articles/cap/learning/psa.htm.
5. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5.
6. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.
7. Luderer AA, Chen YT, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 187-94.
8. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20.
9. Pearson JD, Luderer AA, Metter EJ, et al. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology 1996; 48 (Suppl 6A): 4-9.
10. Froschermaier SE, Pilarsky CP, Wirth MR Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology 1996; 47: 525-8.
11. Marley GM, Miller MC, Kattan MW, et al. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology 1996; 48 (Suppl 6A): 16-22.
12. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996; 48 (Suppl 6A): 55-61.
13. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 518-24.
14. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 152-7.
15. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996; 48 (Suppl 6A): 33-9.
16. Woodrum D, York L. Two-year stability of free and total PSA in frozen serum samples. Urology 1998; 52: 247-51.
17. 1-antichymotrypsin in blood samples. Urology 1996; 48 (Suppl 6A): 81-7.
18. Arcangeli CG, Smith DS, Ratliff TL, Catalona WJ. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol 1997; 158: 2182-7.
19. Jung K, von Klinggräff P, Brux B, Sinha P, Schnorr D, Loening SA. Preanalytical determinants of total and free prostate specific antigen and their ratio: blood collection and storage conditions. Clin Chem 1998; 44: 685-8.
20. Jung K, Lein M, Brux B, Sinha P, Schnorr D, Loening SA. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. Clin Chem Lab Med 2000; 38: 1271-5.
21. Leinonen J, Stenman U-H. Reduced stability of prostate-specific antigen after long-term storage of serum at -20°C. Tumour Biol 2000; 21: 46-53.
22. Ulmert D, Becket C, Nilsson J-Å, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20°C. Clin Chem 2006; 52: 235-9.
23. Paus E, Nilsson O, Bormer OP, Fossa SD, Otnes B, Skovlund E. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J Urol 1998; 159:1599-605.
24. Cartledge JJ, Thompson D, Verril H, Clarkson P, Eardley I. The stability of free and bound prostate-specific antigen. BJU Int 1999; 84: 810-4.
25. Sokoll LJ, Bruzek DJ, Dua R, et al. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 2002; 60 (Suppl 4A): 24-30.
26. Simm B, Gleeson M. Storage conditions for serum for estimating prostate-specific antigen. Clin Chem 1991; 37: 113-4.
27. Deming WE. Statistical adjustment of data. Mineola, NY: Dover Publications, 1984.
28. Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison analysis. Clin Chem 1979; 25: 432-8.
29. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research, 4th ed. Malden, MA: Blackwell Science, 2002.
30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
31. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8: 135-60.
32. Dewitte K, Fierens C, Stöckl D, Thienpont LM. Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice [Letter]. Clin Chem 2002; 48: 799-801.